Head to Head Comparison: Evoke Pharma (NASDAQ:EVOK) versus Supernus Pharmaceuticals (NASDAQ:SUPN)

Evoke Pharma (NASDAQ:EVOK) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability.

Valuation and Earnings

This table compares Evoke Pharma and Supernus Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evoke Pharma	$10.25 million	0.79	-$5.35 million	($2.56)	-2.04
Supernus Pharmaceuticals	$661.82 million	3.90	$73.86 million	$1.15	40.00

Supernus Pharmaceuticals has higher revenue and earnings than Evoke Pharma. Evoke Pharma is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Evoke Pharma has a beta of -0.13, suggesting that its share price is 113% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Evoke Pharma and Supernus Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evoke Pharma	0	0	0	0	0.00
Supernus Pharmaceuticals	0	2	2	0	2.50

Supernus Pharmaceuticals has a consensus price target of $43.00, indicating a potential downside of 6.52%. Given Supernus Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Supernus Pharmaceuticals is more favorable than Evoke Pharma.

Profitability

This table compares Evoke Pharma and Supernus Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evoke Pharma	-42.07%	-99.48%	-33.58%
Supernus Pharmaceuticals	9.70%	14.22%	10.82%

Summary

Supernus Pharmaceuticals beats Evoke Pharma on 12 of the 12 factors compared between the two stocks.

About Evoke Pharma

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.